argenex (NASDAQ:ARGX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of argenex (NASDAQ:ARGX) from a hold rating to a buy rating in a research report sent to investors on Saturday.

Other research analysts have also recently issued research reports about the company. Zacks Research cut argenex from a “hold” rating to a “strong sell” rating in a report on Thursday, January 22nd. Truist Financial lifted their price target on argenex from $950.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Robert W. Baird reaffirmed a “neutral” rating and set a $858.00 price objective (down from $924.00) on shares of argenex in a research note on Thursday, December 18th. Evercore ISI lifted their target price on shares of argenex from $775.00 to $910.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and an average price target of $986.78.

argenex Stock Down 0.6%

Shares of argenex stock opened at $835.68 on Friday. The business has a fifty day simple moving average of $850.70 and a 200-day simple moving average of $786.24. argenex has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The firm has a market cap of $51.71 billion, a price-to-earnings ratio of 35.88, a price-to-earnings-growth ratio of 0.55 and a beta of 0.37.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Abound Wealth Management lifted its stake in shares of argenex by 3,200.0% in the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after purchasing an additional 32 shares during the last quarter. Sound Income Strategies LLC acquired a new position in shares of argenex during the 4th quarter valued at about $28,000. Ameriflex Group Inc. acquired a new position in shares of argenex during the 3rd quarter valued at about $32,000. Sunbelt Securities Inc. bought a new position in shares of argenex in the 3rd quarter valued at approximately $36,000. Finally, Aventura Private Wealth LLC acquired a new stake in argenex in the 4th quarter worth approximately $38,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.